t-butyl 3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate | 1283095-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡喃类
• 英文名称: t-butyl 3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate
• 英文别名: tert-butyl 3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate
• CAS: 1283095-51-1
• 化学式: C₁₈H₂₆FNO₃S
• 分子量: 355.474
• InChiKey: WWYJMWRWOINTKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  67
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  t-butyl 3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 19.5h， 生成 2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N-isopropylpropanamide
  参考文献：
  名称：

  Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography

  摘要：

  Positron emission tomography (PET) coupled to an effective radioligand could provide an important tool for understanding possible links between neuropsychiatric disorders and brain NOP (nociceptin/orphanin FQ peptide) receptors. We sought to develop such a PET radioligand. High-affinity NOP ligands were synthesized based on a 3-(2'-fluoro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)-2(2-halobenzyl)-N-alkylpropanamide scaffold and from experimental screens in rats, with ex vivo LC-MS/MS measures, three ligands were identified for labeling with carbon-11 and evaluation with PET in monkey. Each ligand was labeled by C-11-methylation of an N-desmethyl precursor and studied in monkey under baseline and NOP receptor-preblock conditions. The three radioligands, [C-11] (S) 10a-c, gave similar results. Baseline scans showed high entry of radioactivity into the brain to give a distribution reflecting that expected for NOP receptors. Preblock experiments showed high early peak levels of brain radioactivity, which rapidly declined to a Much lower level than seen in baseline scans, thereby indicating a high level of receptor-specific binding in baseline experiments. Overall, [C-11](S)-10c showed the most favorable receptor-specific signal and kinetics and is now selected for evaluation in human subjects.

  DOI：

  10.1021/jm101487v
• 作为产物：
  描述：

  4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-ium trifluoroacetate 在 2,2,6,6-四甲基哌啶 、 盐酸 、 正丁基锂 、 水 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 异丙醇 为溶剂， 反应 11.5h， 生成 t-butyl 3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate
  参考文献：
  名称：

  SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS

  摘要：

  一个公式为ORL-1受体拮抗剂： 其用途和制备方法已被描述。

  公开号：

  US20110118251A1

文献信息

• [EN] SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE SPIROPIPÉRIDINE EN TANT QU'ANTAGONISTES DE RÉCEPTEUR ORL-1
  申请人：LILLY CO ELI

  公开号：WO2011060217A1

  公开（公告）日：2011-05-19

  An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.

  一种ORL-1受体拮抗剂的公式：描述了其用途以及其制备方法。ORL-1拮抗剂被认为在治疗抑郁症和/或治疗超重、肥胖和/或超重或肥胖后的体重维持治疗中是有用的。某些化合物还通过动物模型证明，本发明的化合物对治疗偏头痛是有用的。
• Spiropiperidine compounds as ORL-1 receptor antagonists
  申请人：Eli Lilly and Company

  公开号：US08232289B2

  公开（公告）日：2012-07-31

  An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.

  本文介绍了一种ORL-1受体拮抗剂的公式、其用途以及制备方法。
• Spiropiperidine compounds as oral-1 receptor antagagonisten
  申请人：Eli Lilly and Company

  公开号：EP2501704B1

  公开（公告）日：2013-09-18
• US8232289B2
  申请人：——

  公开号：US8232289B2

  公开（公告）日：2012-07-31
• SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
  申请人：BENITO COLLADO Ana Belen

  公开号：US20110118251A1

  公开（公告）日：2011-05-19

  An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.

  一个公式为ORL-1受体拮抗剂： 其用途和制备方法已被描述。